Immunome 8-K Signals Major Corporate Event, Broad Shareholder Comms

Ticker: IMNM · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1472012

Immunome Inc. 8-K Filing Summary
FieldDetail
CompanyImmunome Inc. (IMNM)
Form Type8-K
Filed DateJan 11, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentmixed

Complexity: simple

Sentiment: mixed

Topics: corporate-action, merger-acquisition, regulatory-filing

TL;DR

**Immunome's 8-K indicates a major corporate event is underway, requiring broad communication.**

AI Summary

Immunome, Inc. filed an 8-K on January 11, 2024, to disclose that it is simultaneously satisfying filing obligations under Rule 425 of the Securities Act, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c) of the Exchange Act. This indicates that the company is likely involved in a significant corporate event, such as a merger, acquisition, or tender offer, which requires broad communication with shareholders and the public. For investors, this matters because such events can lead to substantial changes in the company's valuation, strategic direction, and future prospects, potentially impacting stock price and long-term investment thesis.

Why It Matters

This filing signals that Immunome is engaged in a significant corporate transaction, which could fundamentally alter the company's structure, operations, and stock value. Investors should pay close attention to subsequent filings for details on the nature of this event.

Risk Assessment

Risk Level: medium — The filing itself doesn't detail the event, creating uncertainty, but the nature of the checked boxes suggests a significant, potentially transformative, corporate action is in progress.

Analyst Insight

A smart investor would monitor Immunome's subsequent SEC filings closely for details regarding the corporate event hinted at by this 8-K, as it could significantly impact the company's valuation and future prospects. Consider the potential implications of a merger or acquisition on existing holdings.

Key Players & Entities

  • Immunome, Inc. (company) — the registrant filing the 8-K
  • January 11, 2024 (date) — date of earliest event reported and filing date
  • Rule 425 (regulation) — written communications under the Securities Act
  • Rule 14a-12 (regulation) — soliciting material under the Exchange Act
  • Rule 14d-2(b) (regulation) — pre-commencement communications under the Exchange Act
  • Rule 13e-4(c) (regulation) — pre-commencement communications under the Exchange Act
  • IMNM (company) — trading symbol for Immunome, Inc.
  • The Nasdaq Capital Market (exchange) — where Immunome's common stock is registered

Forward-Looking Statements

  • Immunome, Inc. will announce details of a merger, acquisition, or tender offer. (Immunome, Inc.) — high confidence, target: Q1 2024
  • The stock price of IMNM will experience volatility upon the announcement of the corporate event. (IMNM) — high confidence, target: Q1 2024

FAQ

What is the primary purpose of Immunome, Inc.'s 8-K filing dated January 11, 2024?

The primary purpose of Immunome, Inc.'s 8-K filing on January 11, 2024, is to indicate that the filing simultaneously satisfies the registrant's obligations under specific provisions of the Securities Act and the Exchange Act, namely Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c).

Which specific SEC rules and regulations are referenced in this 8-K filing by Immunome, Inc.?

Immunome, Inc. references Rule 425 under the Securities Act (17 CFR 230.425), Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12), Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)), and Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) in this 8-K filing.

What is Immunome, Inc.'s trading symbol and on which exchange is its common stock registered?

Immunome, Inc.'s trading symbol is IMNM, and its common stock, with a $0.0001 par value per share, is registered on The Nasdaq Capital Market.

What is the business address and phone number for Immunome, Inc. as stated in the filing?

Immunome, Inc.'s business address is 665 Stockton Drive, Suite 300, Exton, Pennsylvania, 19342, and its telephone number is (610) 321-3700.

What does checking the boxes for Rule 425, 14a-12, 14d-2(b), and 13e-4(c) typically signify for a company?

Checking the boxes for Rule 425, 14a-12, 14d-2(b), and 13e-4(c) typically signifies that the company is involved in a significant corporate transaction, such as a merger, acquisition, tender offer, or other business combination, which requires specific communications and disclosures to shareholders and the public before or during the event.

Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-11 17:27:21

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq

Filing Documents

01 Regulation

Item 7.01 Regulation FD Disclosure. On January 11, 2024, Immunome, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation dated January 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: January 11, 2024 By: /s/ Max Rosett Max Rosett Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.